Title : Donepezil for Alzheimer's disease - Benjamin_2007_Expert.Rev.Neurother_7_1243 |
Author(s) : Benjamin B , Burns A |
Ref : Expert Rev Neurother , 7 :1243 , 2007 |
Abstract :
Donepezil is the most widely prescribed of the cholinesterase inhibitors that has been licensed for the treatment of mild-to-moderate Alzheimer's disease. Evidence from a number of clinical trials suggests that it improves cognitive performance and stabilizes the functional abilities in people with mild-to-moderate Alzheimer's disease. Donepezil increases the amount of the neurotransmitter acetylcholine in the brain, the deficit of which is thought to play a major role in the clinical presentation of Alzheimer's disease. Studies show good safety and long-term tolerability. In addition, donepezil's pharmacokinetic properties make it convenient to prescribe. There are a number of newer drug therapies in various stages of pharmacological development, but donepezil should continue to play a major role in the treatment of Alzheimer's disease for the next few years. |
PubMedSearch : Benjamin_2007_Expert.Rev.Neurother_7_1243 |
PubMedID: 17939763 |
Benjamin B, Burns A (2007)
Donepezil for Alzheimer's disease
Expert Rev Neurother
7 :1243
Benjamin B, Burns A (2007)
Expert Rev Neurother
7 :1243